噻托溴铵吸入剂治疗稳定期D组慢性阻塞性肺疾病38例疗效评价  

Influence of Tiotropium Inhalant on Clinical Symptoms in Stable Stage Group D of COPD and Observation on Its Role for Improving Lung Function in 38 Cases

作　　者：李兆国[1] 吴晓梅[1] 

机构地区：[1]哈尔滨医科大学附属第二医院呼吸内科,黑龙江哈尔滨150086

出　　处：《中国药业》2015年第13期14-15,共2页China Pharmaceuticals

摘　　要：目的探讨稳定期D组慢性阻塞性肺疾病(COPD)患者应用噻托溴铵吸入剂治疗后临床症状的变化及对肺功能的改善作用。方法采用随机单盲法将76例稳定期D组COPD患者均分为观察组和对照组,各38例。对照组给予沙美特罗丙酸氟替卡松吸入剂治疗,观察组在对照组基础上加用噻托溴铵吸入剂。结果两组治疗3,6,12个月时呼吸困难评分及运动耐量均明显优于治疗前(P<0.05),且观察组改善程度更显著(P<0.05);治疗3个月时两组肺功能观察指标均明显优于治疗前(P<0.05),观察组3,6,12个月时肺功能各项指标均明显优于对照组(P<0.05),对照组治疗3个月各指标情况明显优于治疗前、治疗6个月及12个月(P<0.05)。结论噻托溴铵吸入剂治疗稳定期D组慢性阻塞性肺疾病,不仅能显著改善呼吸困难及提高运动耐量,而且还能明显改善肺功能,提高患者生活质量,值得推广。Objective To investigate the change of clinical symptoms after using tiotropium inhalant and its improvement effect on the lung function in the patients with the stable stage group D of chronic obstructive pulmonary disease （ COPD ） . Methods 76 cases of stable stage group D of COPD were selected and divided into the observation group and the control group by adopting the randomized single-blind method, 38 cases in each group. The control group was given salmeterol fluticasone propionate inhalant, on this basis the observation group was added tiotropium bromide powder for inhalation. Results The dyspnea scores and exercise tolerance at 3, 6, 12 months of treatment in the two groups were significantly better than those before treatment, the differences were statistically significant （ P ﹤ 0. 05 ） , moreover the improvement degree in the observation group was significantly superior to those in the control group, the dif-ference was statistically significant （ P ﹤ 0. 05 ）;the lung function indicators at 3 months of treatment in the two groups were significant-ly better than before treatment, the difference was statistically significant （ P ﹤ 0. 05 ）;the lung function indicators at 3, 6, 12 months of treatment in the observation group were significantly better than those in the control group, the differences were statistically significant （ P ﹤ 0. 05 ）;various indicators at 3 months of treatment in the control group were significantly better than before treatment, at 6, 12 months of treatment, the differences were statistically significant （ P ﹤ 0. 05 ） . Conclusion Applying tiotropium inhalant for treating the stable stage group D of COPD not only can significantly improve dyspnea and increase the exercise level, but also significantly improves the lung function, increases the quality of life of patients, and is worthy application in clinical.

关 键 词：慢性阻塞性肺疾病 噻托溴铵吸入剂 沙美特罗丙酸氟替卡松吸入剂 疗效评价 

分 类 号：R969.4[医药卫生—药理学]